Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Atara Biotherapeutics, Inc. (ATRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
7High confidence
0.811Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Atara Biotherapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-CALIFORNIA-INC
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-CALIFORNIA-INC
92%
The Fujifilm MSA includes contractual obligations in the form of payments for the processing rooms and the freezers, each over a term of five years.
PIERRE-FABRE-MEDICAMENT
PIERRE-FABRE-MEDICAMENT
90%
Agreement dated October 31, 2023 with Pierre Fabre Medicament, as amended, from June 30, 2026 to January 1, 2028
Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demo…
Reciprocal relationship from CRBU graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU g…
Atara Biotherapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
PIERRE-FABRE
PIERRE-FABRE
90%
In March 2025, in connection with the transition of manufacturing responsibility for tab-cel to Pierre Fabre, we assigned the Fujifilm MSA to Pierre Fabre.
PIERRE-FABRE-MEDICAMENT
PIERRE-FABRE-MEDICAMENT
90%
Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milest…
Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
Reciprocal relationship from JNJ graph: Reciprocal relationship from ATRA graph: elay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could b…
elay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product…
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-CALIFORNIA-INC
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-CALIFORNIA-INC
62%
aggregate of up to $ 556.0 million in additional potential milestone payments upon achieving certain regulatory and commercial milestones relating to tab-cel in the Additional Territory, including up…
Atara Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ATRA-DEBT-7955
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2014-12-31.
ATRA-DEBT
Debt stack $9.1M
90%
Market cache reports total debt of $9.1M.
Atara Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Atara Biotherapeutics, Inc..
Atara Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ATRA-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C
ADAGE CAPITAL PARTNERS GP, L.L.C.
90%
13F overlay lists ADAGE CAPITAL PARTNERS GP, L.L.C. as top holder; 35 tracked holders.
Atara Biotherapeutics, Inc. Extended Supply Chain Network
